S
Sheila Jacobson
Researcher at University of Toronto
Publications - 30
Citations - 1989
Sheila Jacobson is an academic researcher from University of Toronto. The author has contributed to research in topics: Pregnancy & Randomized controlled trial. The author has an hindex of 16, co-authored 30 publications receiving 1823 citations. Previous affiliations of Sheila Jacobson include Purdue Pharma.
Papers
More filters
Journal ArticleDOI
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies
Laura Y. Park-Wyllie,Paolo Mazzotta,Anne Pastuszak,Myla E Moretti,Lizanne Beique,Laura Hunnisett,Mark H. Friesen,Sheila Jacobson,S. Kasapinovic,Debra Chang,Orna Diav-Citrin,David Chitayat,Irena Nulman,Thomas R. Einarson,Gideon Koren +14 more
TL;DR: Although prednisone does not represent a major teratogenic risk in humans at therapeutic doses, it does increase by an order of 3.4-fold the risk of oral cleft, which is consistent with the existing animal studies.
Journal ArticleDOI
Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester.
Sheila Jacobson,L. Ceolin,P. Kaur,Anne Pastuszak,Tom Einarson,Gideon Koren,K. Jones,K. Johnson,D. Sahn,A. E. Donnenfeld,Michael J. Rieder,R. Santelli +11 more
TL;DR: The results indicate that lithium is not an important human teratogen and women with major affective disorders who wish to have children may continue lithium therapy, provided that adequate screening tests, including level II ultrasound and fetal echocardiography, are done.
Journal ArticleDOI
Probiotics for Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating Lactobacillus reuteri DSM 17938
Kim Chau,Eddy Lau,Saul Greenberg,Sheila Jacobson,Parvaneh Yazdani-Brojeni,Natasha Verma,Gideon Koren +6 more
TL;DR: Administration of L reuteri DSM 17938 significantly improved colic symptoms by reducing crying and fussing times in breastfed Canadian infants with colic.
Journal ArticleDOI
Tissue plasminogen activator for the treatment of thromboembolism in infants and children
Maurice Levy,Lee N. Benson,Patricia E. Burrows,Yedidia Bentur,Dawn K Strong,Joanne Smith,David W. Johnson,Sheila Jacobson,Gideon Koren +8 more
TL;DR: It is concluded that tissue plasminogen activator is effective in inducing clot lysis in children and it is recommended that a dose of 0.1 mg/kg per hour be started and increased gradually if clot dissolution does not occur, with close monitoring for bleeding.
Journal ArticleDOI
Randomised trial of oral morphine for painful episodes of sickle-cell disease in children
TL;DR: Oral, controlled-release morphine is a reliable, non-invasive alternative to continuous intravenous morphine for the management of painful episodes of sickle-cell disease in children.